Protein kinase c-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma cells

Journal of Investigative Medicine

Volumn 60, Issue 1, 2012, Pages 29-38

  Saba, Nakhle S ^a,b   Levy, Laura S ^b  

^a Department of Medicine Section of Hematology and Medical Oncology   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS related lymphoma; Apoptosis; Cell cycle inhibition; Protein kinase C beta; Targeted therapy

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA 1; PROTEIN KINASE C BETA 2; PROTEIN S6; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NICK END LABELING; NONHODGKIN LYMPHOMA; PROTEIN PHOSPHORYLATION;

MAMMALIA;

EID: 84856692330     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318237eb55     Document Type: Article

References (58)

1. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol. 2006;33: 407-420. (Pubitemid 44142738)
2. Leonard JP, Martin P, Barrientos J, et al. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol. 2008;45: S11-S16.
3. Serova M, Ghoul A, Benhadji KA, et al. Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol. 2006;33: 466-478. (Pubitemid 44160726)
4. Wood C, Harrington W Jr. AIDS and associated malignancies. Cell Res. 2005;15: 947-952. (Pubitemid 41826264)
5. Aoki Y, Tosato G. Neoplastic conditions in the context of HIV-1 infection. Curr HIV Res. 2004;2: 343-349. (Pubitemid 39242964)
6. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDSYdefining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104: 1505-1511. (Pubitemid 41356166)
7. Krause J. AIDS-related non-Hodgkin's lymphomas. Microsc Res Tech. 2005;68: 168-175. (Pubitemid 41696967)
8. Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113: 1213-1224.
9. Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol. 2005;130: 662-670. (Pubitemid 43906640)
10. Bellan C, Lazzi S, De Falco G, et al. Burkitt's lymphoma: new insights into molecular pathogenesis. J Clin Pathol. 2003;56: 188-192. (Pubitemid 36308032)
11. Martiny-Baron G, Fabbro D. Classical PKC isoforms in cancer. Pharmacol Res. 2007;55: 477-486. (Pubitemid 46970734)
12. Reyland ME. Protein kinase C and apoptosis. In: Srivastava R, ed. Apoptosis, Cell Signaling and Human Disease. Totowa, NJ: Humana Press, Inc;2007: 31-55.
13. Guo B, Su TT, Rawlings DJ. Protein kinase C family functions in B-cell activation. Curr Opin Immunol. 2004;16: 367-373. (Pubitemid 38595376)
14. Shinohara H, Maeda S, Watarai H, et al. I kappa B kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells. J Exp Med. 2007;204: 3285-3293.
15. Su TT, Guo B, Kawakami Y, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol. 2002;3: 780-786.
16. Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs. 2008;17: 939-944.
17. Deacon EM, Pongracz J, Griffiths G, et al. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol. 1997;50: 124-131. (Pubitemid 27454996)
18. Choi PM, Tchou-Wong KM, Weinstein IB. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol Cell Biol. 1990;10: 4650-4657.
19. Jiang XH, Tu SP, Cui JT, et al. Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis. Cancer Res. 2004;64: 5787-5794.
20. Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010;12: 608-613.
21. Jian W, Yamashita H, Levitt JM, et al. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther. 2009;8: 1772-1778.
22. Rieger J, Lemke D, Maurer G, et al. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem. 2008;106: 2436-2448.
23. Spindler KL, Lindebjerg J, Lahn M, et al. Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer. Int J Colorectal Dis. 2009;24: 641-645.
24. Tanai C, Yamamoto N, Ohe Y, et al. A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer. J Thorac Oncol. 2010;5: 1068-1074.
25. Tekle C, Giovannetti E, Sigmond J, et al. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer. 2008;99: 750-759.
26. Vogl UM, Berger W, Micksche M, et al. Synergistic effect of sorafenib and sunitinib with enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Lett. 2009;277: 218-226.
27. Yin X, Hayes DN, Shores CG. Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma. Head Neck. 2010.
28. Civallero M, Cosenza M, Grisendi G, et al. Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leuk Lymphoma. 2010;51: 671-679.
29. Holler C, Pinon JD, Denk U, et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood. 2009;113: 2791-2794.
30. Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004;101: 3118-3123. (Pubitemid 38327744)
31. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol. 2006;126: 1641-1647.
32. Raab MS, Breitkreutz I, Tonon G, et al. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009;113: 1513-1521.
33. Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase C beta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther. 2006;5: 1783-1789. (Pubitemid 44323246)
34. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8: 68-74. (Pubitemid 34101731)
35. Verdelli D, Nobili L, Todoerti K, et al. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematol Oncol. 2009;27: 23-30.
36. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol. 2005;18: 1377-1384. (Pubitemid 41348658)
37. Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol. 2007;19: 590-595.
38. Riihijarvi S, Koivula S, Nyman H, et al. Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. Mod Pathol. 2010;23: 686-693.
39. Schaffel R, Morais JC, Biasoli I, et al. PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma. Mod Pathol. 2007;20: 326-330. (Pubitemid 46348328)
40. Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol. 2008;19: 247-253. (Pubitemid 351209293)
41. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007;25: 1741-1746. (Pubitemid 46797955)
42. Saba NS, Levy LS. Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase C inhibito. Leuk Lymphoma. 2011;52: 877-886.
43. Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008;49: 1374-1383. (Pubitemid 352015802)
44. Ng VL, Hurt MH, Fein CL, et al. IgMs produced by two acquired immune deficiency syndrome lymphoma cell lines: Ig binding specificity and VH-gene putative somatic mutation analysis. Blood. 1994;83: 1067-1078.
45. Renne R, Zhong W, Herndier B, et al. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996;2: 342-346. (Pubitemid 26080656)
46. Ruff KR, Puetter A, Levy LS. Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer. 2007;7: 35.
47. Tanaka M, Sagawa S, Hoshi J, et al. Synthesis of anilino- monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004;14: 5171-5174. (Pubitemid 39233388)
48. Lee KW, Kim SG, Kim HP, et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res. 2008;68: 1916-1926.
49. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15: 6541-6551. (Pubitemid 26413787)
50. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3, 4, 5-trisphosphate-dependent activation of protein kinase B. Science. 1998;279: 710-714. (Pubitemid 28144551)
51. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378: 785-789. (Pubitemid 26004411)
52. Fang X, Yu S, Tanyi JL, et al. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol. 2002;22: 2099-2110. (Pubitemid 34224618)
53. Serova M, Astorgues-Xerri L, Bieche I, et al. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase C beta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther. 2010;9: 1308-1317.
54. Luo W, Yan G, Li L, et al. Epstein-Barr virus latent membrane protein 1 mediates serine 25 phosphorylation and nuclear entry of annexin A2 via PI-PLC-PKCalpha/PKCbeta pathway. Mol Carcinog. 2008;47: 934-946.
55. Kuo WL, Liu J, Mauceri H, et al. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010;9: 2814-2824.
56. Kim SG, Lee SJ. PI3K, RSK, and mTOR signal networks for the GST gene regulation. Toxicol Sci. 2007;96: 206-213. (Pubitemid 46432017)
57. Civallero M, Cosenza M, Neri A, et al. Genomic profiling of enzastaurin-treated B cell lymphoma RL cells. Head Neck. 2011;33: 1106-1114.
58. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65: 7462-7469. (Pubitemid 41161281)